Published in J Cell Biochem on September 01, 2011
LRP5 and LRP6 in development and disease. Trends Endocrinol Metab (2013) 1.21
Transglutaminase 2-mediated activation of β-catenin signaling has a critical role in warfarin-induced vascular calcification. Arterioscler Thromb Vasc Biol (2011) 0.91
From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD. Pediatr Nephrol (2015) 0.89
The role of Lrp5/6 in cardiac valve disease: experimental hypercholesterolemia in the ApoE-/- /Lrp5-/- mice. J Cell Biochem (2011) 0.87
Defining the role of fluid shear stress in the expression of early signaling markers for calcific aortic valve disease. PLoS One (2013) 0.87
Oxidative-mechanical stress signals stem cell niche mediated Lrp5 osteogenesis in eNOS(-/-) null mice. J Cell Biochem (2012) 0.87
Myxomatous mitral valve disease bench to bedside: LDL-density-pressure regulates Lrp5. Expert Rev Cardiovasc Ther (2014) 0.86
Quercetin attenuates warfarin-induced vascular calcification in vitro independently from matrix Gla protein. J Biol Chem (2012) 0.84
Simulation of early calcific aortic valve disease in a 3D platform: A role for myofibroblast differentiation. J Mol Cell Cardiol (2016) 0.78
Noncanonical Wnts at the Cusp of Fibrocalcific Signaling Processes in Human Calcific Aortic Valve Disease. Arterioscler Thromb Vasc Biol (2017) 0.75
LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell (2001) 11.99
High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med (2002) 11.28
Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med (1999) 8.14
Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol (1997) 7.45
A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet (2001) 6.56
An LDL-receptor-related protein mediates Wnt signalling in mice. Nature (2000) 6.34
Bone formation and inflammation in cardiac valves. Circulation (2001) 6.01
Human aortic valve calcification is associated with an osteoblast phenotype. Circulation (2003) 4.49
A mechanism for Wnt coreceptor activation. Mol Cell (2004) 4.31
LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science (2007) 4.27
Osteopontin is expressed in human aortic valvular lesions. Circulation (1995) 4.16
Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med (2000) 4.13
Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J Clin Invest (1994) 3.97
Wnt signaling in osteoblasts and bone diseases. Gene (2004) 3.72
High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res (2003) 3.48
Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest (2005) 3.00
Non-invasive assessment of aortic stenosis by Doppler ultrasound. Br Heart J (1980) 2.96
Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol (2006) 2.95
Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion. Proc Natl Acad Sci U S A (2002) 2.93
Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation (2002) 2.93
Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation (2001) 2.55
Caveolin is necessary for Wnt-3a-dependent internalization of LRP6 and accumulation of beta-catenin. Dev Cell (2006) 2.49
Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J Bone Miner Res (2004) 2.46
New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation (2000) 2.19
The multiple phases and faces of wnt signaling during cardiac differentiation and development. Circ Res (2010) 2.04
Apparently normal mitral valves in patients with heart failure demonstrate biochemical and structural derangements: an extracellular matrix and echocardiographic study. J Am Coll Cardiol (2005) 1.99
Cardiac valve calcification: characteristics of patients with calcification of the mitral annulus or aortic valve. Heart (1997) 1.97
Cloning of a novel member of the low-density lipoprotein receptor family. Gene (1998) 1.97
Isolation and characterization of LRP6, a novel member of the low density lipoprotein receptor gene family. Biochem Biophys Res Commun (1998) 1.93
Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation (2005) 1.88
Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone. J Bone Miner Res (2009) 1.85
Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol (2001) 1.72
Hypercholesterolemic aortic-valve disease. N Engl J Med (2003) 1.71
Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart (2005) 1.65
Glycosylation and palmitoylation of Wnt-3a are coupled to produce an active form of Wnt-3a. Genes Cells (2007) 1.55
A new low density lipoprotein receptor related protein, LRP5, is expressed in hepatocytes and adrenal cortex, and recognizes apolipoprotein E. J Biochem (1998) 1.53
Severe hypercholesterolemia, impaired fat tolerance, and advanced atherosclerosis in mice lacking both low density lipoprotein receptor-related protein 5 and apolipoprotein E. J Biol Chem (2002) 1.53
Factors associated with calcific aortic valve degeneration in the elderly. Eur Heart J (1994) 1.48
Bone biomechanical properties in LRP5 mutant mice. Bone (2004) 1.47
LRP5 and Wnt signaling: a union made for bone. J Bone Miner Res (2004) 1.45
Detection of osteopontin in calcified human aortic valves. Arterioscler Thromb Vasc Biol (1997) 1.41
Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis. Am J Pathol (2001) 1.33
Molecular cloning and characterization of LR3, a novel LDL receptor family protein with mitogenic activity. Biochem Biophys Res Commun (1998) 1.32
Glycosaminoglycans and proteoglycans in normal mitral valve leaflets and chordae: association with regions of tensile and compressive loading. Glycobiology (2004) 1.30
Correlation of serum lipids, calcium, and phosphorus, diabetes mellitus and history of systemic hypertension with presence or absence of calcified or thickened aortic cusps or root in elderly patients. Am J Cardiol (1987) 1.26
Kremen is required for neural crest induction in Xenopus and promotes LRP6-mediated Wnt signaling. Development (2007) 1.25
Wnt signaling in heart valve development and osteogenic gene induction. Dev Biol (2009) 1.22
Development and progression of aortic valve stenosis: atherosclerosis risk factors--a causal relationship? A clinical morphologic study. Clin Cardiol (1991) 1.17
Relation between cardiovascular risk factors and nonrheumatic severe calcific aortic stenosis among patients with a three-cuspid aortic valve. Am J Cardiol (2003) 1.15
Case-controlled study to assess risk factors for aortic stenosis in congenitally bicuspid aortic valve. Am J Cardiol (2001) 1.14
Experimental hypercholesterolemia induces apoptosis in the aortic valve. J Heart Valve Dis (2001) 1.10
Mutation in EGFP domain of LDL receptor-related protein 6 impairs cellular LDL clearance. Circ Res (2008) 1.08
Quantitative structural analysis of collagen in chordae tendineae and its relation to floppy mitral valves and proteoglycan infiltration. Br Heart J (1987) 1.08
A common variant in low-density lipoprotein receptor-related protein 6 gene (LRP6) is associated with LDL-cholesterol. Arterioscler Thromb Vasc Biol (2009) 1.04
Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis. J Am Coll Cardiol (2006) 1.03
Epidemiology and cardiovascular risk factors of aortic stenosis. Cardiovasc Ultrasound (2006) 1.01
Case-control analysis of risk factors for presence of aortic stenosis in adults (age 50 years or older). Am J Cardiol (1985) 0.98
Atorvastatin decreases cellular proliferation and bone matrix expression in the hypercholesterolemic mitral valve. J Am Coll Cardiol (2005) 0.97
The floppy, myxomatous mitral valve, mitral valve prolapse, and mitral regurgitation. Prog Cardiovasc Dis (1991) 0.96
Association between calcific aortic stenosis and hypercholesterolemia: is there a need for a randomized controlled trial of cholesterol-lowering therapy? Clin Cardiol (2001) 0.95
Parameters of LRP5 from a structural and molecular perspective. Crit Rev Eukaryot Gene Expr (2005) 0.95
Diabetes and hypercholesterolemia among patients with calcific aortic stenosis. J Chronic Dis (1984) 0.94
A case-control investigation of the relation between hyperlipidaemia and calcific aortic valve stenosis. Heart (1997) 0.90
Association of mitral annular calcium with symptomatic peripheral arterial disease in older persons. Am J Cardiol (2001) 0.85
Gene targeting approaches in mice: assessing the roles of LRP5 and LRP6 in osteoblasts. J Musculoskelet Neuronal Interact (2009) 0.85